PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
نویسندگان
چکیده
Methods Eighty-five (85) patients with JIA receiving etanercept in combination with MTX (etanercept/MTX) and 71 patients receiving MTX alone were enrolled at the Division of Rheumatology, Bambino Gesù Children’s Hospital, Rome, Italy. Incidence rates were calculated as the number of varicella cases, herpes zoster episodes and herpes labialis episodes per patient-years of follow-up (under specific treatment).
منابع مشابه
PReS-FINAL-2080: Overlap syndrome between primary sclerosing cholangitis and autoimmune hepatitis associated with ulcerative colitis - a case of unusual presentation in a patient with systemic juvenile idiopathic arthritis
Introduction Systemic juvenile idiopathic arthritis (systemic-JIA) is characterized by the presence of arthritis associated with systemic manifestations and an important inflammatory response, being always a clinical diagnosis of exclusion. The association of systemic-JIA with autoimmune diseases is uncommon. The authors found only one description of systemic-JIA associated with autoimmune hepa...
متن کاملHerpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
Incidence rates for varicella and herpes zoster were similar in patients with juvenile idiopathic arthritis receiving etanercept/methotrexate (n = 85, 184.9 patient-years [PY]) or methotrexate alone (n = 71, 199.4 PY); no complicated varicella or herpes zoster cases were reported; herpes labialis incidence was higher in patients receiving etanercept/methotrexate versus methotrexate alone (0.38 ...
متن کاملPReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
Introduction Induction of inactive disease (ID) in Juvenile Idiopathic Arthritis (JIA) is the main target of all current regimes, as it will maintain physical ability and hinder disease associated-damage. Early predictive markers for the future achievement of ID in patients under expensive therapies are therefore urgently needed in the era of financial recession. Our previous published experien...
متن کاملPReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
Methods Samples were collected from 71 JIA patients (43 polyarthritis (12 RF positive), 18 extendend oligoarthritis, 3 persistent oligoarthritis, 1 enthesitis related arthritis, 6 psoriatic arthritis) included in the Dutch Arthritis and Biologics in Children (ABC) Register treated with etanercept. The patients were categorized into responders (acrpedi≥50) (n = 55) and non-responders (acrpedi≤50...
متن کاملPReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
Results Ten 3 to 16-year-old children were included for VZV (n = 8), CMV (n = 2) or EBV (n = 1) primoinfection while on etanercept (n = 1), adalimumab (n = 2), anakinra (n = 2) or canakinumab (n = 6). Seven patients had concomitant non-steroidal anti-inflammatory (NSAID) treatment, 7 low dose predniso(lo)ne and 4 methotrexate. The 8 patients with VZV infection developed typical skin disease and...
متن کامل